Abstract | BACKGROUND: AIMS: METHODS: MGLVA1 cells (which have a gastrin autocrine/paracrine phenotype) and ST16 cells (which have an endocrine phenotype) were injected into the peritoneal cavity of SCID mice. Peritoneal tumours, ascites, and cachexia formation occurred, with the monitored endpoint being morbidity. RESULTS: In MGLVA1 cells, intravenous administration of antibodies raised against Gastrimmune increased the 50% median survived by 25% at three different initial cell seeding concentrations (1 x 10(6)-5 x 10(5) per mouse). In ST16 cells, the effect of Gastrimmune induced antibodies on time to morbidity was greatest at the lowest cell seeding concentration (5 x 10(5) cells/mouse) with the 50% median survival increased by 74% and overall survival achieved in 38% of the mice. CONCLUSIONS:
Gastrimmune may have potential therapeutic benefit on gastrin sensitive gastric tumours and may interact with both endocrine and autocrine mediated growth pathways.
|
Authors | S A Watson, T M Morris, A Varro, D Michaeli, A M Smith |
Journal | Gut
(Gut)
Vol. 45
Issue 6
Pg. 812-7
(Dec 1999)
ISSN: 0017-5749 [Print] England |
PMID | 10562577
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cancer Vaccines
- Culture Media, Serum-Free
- Diphtheria Toxoid
- Gastrins
- gastrin immunogen
|
Topics |
- Animals
- Autocrine Communication
(physiology)
- Cancer Vaccines
- Culture Media, Serum-Free
- Diphtheria Toxoid
(therapeutic use)
- Gastrins
(metabolism, therapeutic use)
- Humans
- Immunization, Passive
- Luminescent Measurements
- Mice
- Mice, SCID
- Neoplasm Transplantation
- Neoplasms, Hormone-Dependent
(pathology, therapy)
- Paracrine Communication
(physiology)
- Reverse Transcriptase Polymerase Chain Reaction
- Stomach Neoplasms
(pathology, therapy)
- Tumor Cells, Cultured
|